Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Zacks.com on MSN22h
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/YUltragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback